US Archives - Page 3 of 79 - European Medical Journal

FDA Fast Track Therapy Targets HER2-Mutated NSCLC: AACR 2025

Promising new data emerged on zongertinib, an investigational oral therapy targeting HER2 mutations in advanced non-small cell lung cancer (NSCLC), was presented at the AACR Annual Meeting 2025 in Chicago.

Are JAK Inhibitors Raising VTE Risk in Rheumatoid Arthritis?

In patients with rheumatoid arthritis (RA), understanding the risk of venous thromboembolism (VTE) is increasingly important as treatment strategies evolve.

Liquid Biopsy Detects Colorectal Cancer Recurrence Months Early: AACR 2025

At the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, new data revealed that a liquid biopsy using circulating tumor DNA (ctDNA) could detect colorectal cancer recurrence significantly earlier than imaging, with ctDNA signals appearing up to 416 days before clinical detection.

Acne Scar Treatments Evolve: Key Therapies Reviewed

Persistent acne scarring remains a major concern for patients and clinicians alike, with many individuals turning to invasive procedures in search of effective relief.

Off-the-Shelf Cell Therapy Induces Remission in Relapsed AML: AACR 2025

At the AACR Annual Meeting 2025 in Chicago, researchers unveiled promising early results from a novel cell therapy that could reshape treatment options for patients with relapsed or refractory acute myeloid leukemia (AML).

Immunotherapy Removes Surgery Need in dMMR Cancers: AACR 2025

Neoadjuvant immunotherapy using PD-1 blockade has demonstrated the potential to eliminate the need for surgery in patients with early-stage mismatch repair-deficient (dMMR) cancers, according to groundbreaking data presented at the AACR Annual Meeting 2025.

Parkinson’s Gut Clues: How REM Sleep Disorder Shapes Microbiome Dynamics

In Parkinson’s disease (PD), gut microbiome imbalances and early symptoms like REM sleep behavior disorder (RBD) are increasingly recognized as clues to the condition’s origins and progression.

Oral Therapy in KRAS G12D-mutated Lung Cancer: AACR 2025

At the AACR 2025 Annual Meeting in Chicago, new data presented on the investigational agent zoldonrasib showed encouraging clinical activity in patients with non-small cell lung cancer (NSCLC) harboring the KRAS G12D mutation.

Should ICU Transfusions Be Limited? New Guidance

In critically ill adults, fresh frozen plasma (FFP) and platelet transfusions are commonly administered, but new guidance urges caution.

Lung Nodule Diagnosis Delays Tied to Demographics

Timely lung cancer diagnosis and treatment are essential for improved survival, but new research shows that patients with suspicious lung nodules continue to experience critical delays at multiple stages of care.